OMER · XBRL financial data

Omeros financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OMER's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	73,813	—	—	—	—	—
Cost of goods and services sold	902	—	—	—	—	—
Research and development	110,817	118,775	112,721	114,870	119,523	81,296
Selling, general and administrative	—	54,842	50,668	49,660	49,735	41,500
General and administrative	72,695	54,842	50,668	—	—	—
Operating income (loss)	(110,601)	(173,617)	(163,389)	(164,530)	(169,258)	(122,796)
Interest income	—	—	2,200	14,700	8,400	2,300
Interest expense	26,751	19,669	22,702	30,844	24,675	(960)
Other income (expense)	654	1,740	—	—	—	—
Income tax expense (benefit)	(12,011)	0	0	0	2,305	2,012
Net income (loss)	(138,061)	194,235	47,417	(117,813)	(156,815)	(3,350)
Earnings per share, basic USD per share	(2.41)	3.12	0.76	(1.88)	(2.70)	(0.05)
Earnings per share, diluted USD per share	(2.41)	3.12	0.76	(1.88)	(2.70)	(0.05)
Weighted average shares, basic thousands of shares	57,177	62,344	62,737	62,739	58,171	63,510
Weighted average shares, diluted thousands of shares	57,177	62,344	62,737	—	—	—

Fiscal years (OMER's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	10,501	100,808	11,009	7,105	3,400	9,660
Short-term investments	124,452	56,458	183,909	164,743	86,732	162,144
Marketable securities	—	—	183,931	164,762	—	—
Accounts receivable	—	—	—	—	—	0
Inventory	1,355	—	—	—	—	0
Prepaid and other current assets	11,136	8,149	6,300	8,581	7,166	7,595
Total current assets	151,285	247,889	443,236	217,898	134,120	215,667
Property and equipment, net	—	—	1,492	1,950	2,678	1,768
Right-of-use asset	25,526	28,276	21,762	18,631	14,961	10,708
Total assets	181,042	419,268	590,969	378,269	277,079	325,632
Accounts payable	4,199	13,400	5,989	7,712	5,905	4,764
Accrued liabilities	28,755	33,134	30,551	31,868	26,005	29,388
Total current liabilities	36,736	51,789	136,383	53,316	79,526	78,062
Lease liability, non-current	28,032	28,811	21,971	17,424	12,224	6,524
Accumulated deficit	(872,672)	(683,134)	(635,717)	(753,530)	(910,345)	(913,695)
Total stockholders' equity	(120,752)	23,780	85,684	(24,983)	(182,609)	(121,231)
Total liabilities and equity	181,042	419,268	590,969	378,269	277,079	325,632
Common shares outstanding (cover page) thousands of shares	61,934	62,727	62,829	57,943	58,064	71,996

Fiscal years (OMER's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(138,061)	194,235	47,417	(117,813)	(156,815)	(3,350)
Stock-based compensation	14,925	17,630	14,072	11,650	10,493	8,192
Depreciation and amortization	—	1,386	952	920	950	964
Net cash from operating activities	(100,086)	(109,722)	(86,483)	74,726	(148,803)	(116,094)
Purchases of property and equipment	283	277	113	426	165	65
Net cash from investing activities	(67,031)	193,710	(127,564)	27,454	82,217	164,523
Proceeds from issuing common stock	93,675	—	—	—	—	—
Share repurchases	—	0	0	4,654	11,851	0
Net cash from financing activities	174,534	6,319	124,248	(106,084)	62,881	(42,169)
Net change in cash	7,417	90,307	(89,799)	(3,904)	(3,705)	6,260

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Omeros	1,988	28,529	4,149*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Lexicon Pharmaceuticals	40,924	692	(9,192)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	85,600	12,318	6,121	12.5M	—	Q1 FY26 10-QMar 31, 2026
Crescent Biopharma	171,593	0	(19,463)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
Editas Medicine	181,815	11,890	(29,568)*	153.6M	7.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.